GlassScriptPhysician profile
Yong Tan
NPI 1083771489
$6,553.73
in general payments reported to CMS, 2019-2025
33 companies · $845 in 2025
The $845 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $1,287 · 2021: $1,136 · 2022: $678 · 2023: $567 · 2024: $1,003 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,230.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $922.38 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $831.83 | 2019-2022 | |
| Glaxosmithkline, LLC. | $396.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $385.59 | 2019-2022 | |
| Lilly USA, LLC | $379.06 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $287.59 | 2019-2022 | |
| Corcept Therapeutics | $214.24 | 2020-2025 | Korlym |
| Amgen INC. | $205.43 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $185.72 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $164.35 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $134.62 | 2024 | Voquezna |
| Boston Scientific Corporation | $125.00 | 2022 | |
| Pfizer INC. | $124.99 | 2020-2022 | |
| Abbvie INC. | $108.14 | 2020-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.17 | 2022-2025 | Jardiance, Tradjenta |
| Ironwood Pharmaceuticals, INC | $87.79 | 2019-2024 | |
| Astellas Pharma US INC | $87.35 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.15 | 2021-2023 | |
| Globus Medical, INC. | $84.08 | 2025 | Senza |
| Biohaven Pharmaceuticals, INC. | $60.14 | 2020-2021 | |
| Exact Sciences Corporation | $56.63 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $49.88 | 2020 | |
| Stryker Corporation | $43.39 | 2025 | Viaflow, Pangea, Prostep Mica |
| Esperion Therapeutics, INC. | $42.77 | 2020-2021 | |
| Daiichi Sankyo INC. | $29.99 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.29 | 2019 | |
| Viiv Healthcare Company | $23.46 | 2020 | |
| Baxter Healthcare | $22.28 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Teva Pharmaceuticals USA, INC. | $14.21 | 2020 | |
| Strongbridge US INC. | $12.83 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.10 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.